Published in Lancet Neurol on December 25, 2008
Thrombolysis for acute ischaemic stroke. Cochrane Database Syst Rev (2014) 1.76
Imaging recommendations for acute stroke and transient ischemic attack patients: A joint statement by the American Society of Neuroradiology, the American College of Radiology, and the Society of NeuroInterventional Surgery. AJNR Am J Neuroradiol (2013) 1.71
Pretreatment diffusion- and perfusion-MR lesion volumes have a crucial influence on clinical response to stroke thrombolysis. J Cereb Blood Flow Metab (2010) 1.68
Computed tomography in acute ischemic stroke. Neuroradiology (2009) 1.64
Acute stroke magnetic resonance imaging: current status and future perspective. Neuroradiology (2009) 1.59
Greater effect of stroke thrombolysis in the presence of arterial obstruction. Ann Neurol (2011) 1.44
An ethical hierarchy for decision making during medical emergencies. Ann Neurol (2010) 1.43
Multiparametric MRI and CT models of infarct core and favorable penumbral imaging patterns in acute ischemic stroke. Stroke (2012) 1.43
Perfusion computed tomography to assist decision making for stroke thrombolysis. Brain (2015) 1.41
The value of arterial spin-labeled perfusion imaging in acute ischemic stroke: comparison with dynamic susceptibility contrast-enhanced MRI. Stroke (2012) 1.40
von Willebrand factor: an emerging target in stroke therapy. Stroke (2011) 1.34
Reperfusion is a more accurate predictor of follow-up infarct volume than recanalization: a proof of concept using CT in acute ischemic stroke patients. Stroke (2009) 1.27
Extracellular chromatin is an important mediator of ischemic stroke in mice. Arterioscler Thromb Vasc Biol (2012) 1.17
Imaging-based treatment selection for intravenous and intra-arterial stroke therapies: a comprehensive review. Expert Rev Cardiovasc Ther (2011) 1.14
Imaging of acute stroke. Nat Rev Neurol (2010) 1.09
Prospective study on the mismatch concept in acute stroke patients within the first 24 h after symptom onset - 1000Plus study. BMC Neurol (2009) 1.08
Refining the mismatch concept in acute stroke: lessons learned from PET and MRI. J Cereb Blood Flow Metab (2012) 1.07
Use of magnetic resonance imaging to predict outcome after stroke: a review of experimental and clinical evidence. J Cereb Blood Flow Metab (2010) 1.01
Adjunctive and alternative approaches to current reperfusion therapy. Stroke (2012) 1.00
Comparison of arterial spin labeling and dynamic susceptibility contrast perfusion MRI in patients with acute stroke. PLoS One (2013) 0.99
Ischemia-reperfusion injury in stroke. Interv Neurol (2013) 0.94
Machine learning for outcome prediction of acute ischemic stroke post intra-arterial therapy. PLoS One (2014) 0.94
Imaging in Endovascular Stroke Trials. J Neuroimaging (2015) 0.93
Edaravone (Radicut), a free radical scavenger, is a potentially useful addition to thrombolytic therapy in patients with acute ischemic stroke. Biomed Rep (2012) 0.91
Imaging stroke patients with unclear onset times. Neuroimaging Clin N Am (2011) 0.90
Quantitative analysis of hypoperfusion in acute stroke: arterial spin labeling versus dynamic susceptibility contrast. Stroke (2013) 0.89
Recanalization therapies in acute ischemic stroke: pharmacological agents, devices, and combinations. Stroke Res Treat (2009) 0.89
Imaging of acute ischemic stroke. Neuroimaging Clin N Am (2010) 0.89
MR perfusion imaging in acute ischemic stroke. Neuroimaging Clin N Am (2011) 0.89
Postischemic hyperperfusion on arterial spin labeled perfusion MRI is linked to hemorrhagic transformation in stroke. J Cereb Blood Flow Metab (2015) 0.88
Wake-up stroke: clinical characteristics, imaging findings, and treatment option - an update. Front Neurol (2014) 0.88
Perfusion MRI: the five most frequently asked clinical questions. AJR Am J Roentgenol (2013) 0.88
Subacute intranasal administration of tissue plasminogen activator increases functional recovery and axonal remodeling after stroke in rats. Neurobiol Dis (2011) 0.88
Current perspectives on the use of intravenous recombinant tissue plasminogen activator (tPA) for treatment of acute ischemic stroke. Vasc Health Risk Manag (2014) 0.88
Magnetic resonance diffusion-perfusion mismatch in acute ischemic stroke: An update. World J Radiol (2012) 0.87
Prediction of infarct volume and neurologic outcome by using automated multiparametric perfusion-weighted magnetic resonance imaging in a primate model of permanent middle cerebral artery occlusion. J Cereb Blood Flow Metab (2010) 0.87
Endothelial cells and astrocytes: a concerto en duo in ischemic pathophysiology. Int J Cell Biol (2012) 0.86
Current status and future role of brain PET/MRI in clinical and research settings. Eur J Nucl Med Mol Imaging (2015) 0.86
Comparisons of Analysis Methods for Proof-of-Concept Trials. CPT Pharmacometrics Syst Pharmacol (2013) 0.85
Simultaneous PET/MRI in stroke: a case series. J Cereb Blood Flow Metab (2015) 0.85
Dynamic functional cerebral blood volume responses to normobaric hyperoxia in acute ischemic stroke. J Cereb Blood Flow Metab (2012) 0.85
Quantitative cerebral MR perfusion imaging: preliminary results in stroke. J Magn Reson Imaging (2010) 0.84
Analysis of the National Institute of Neurological Disorders and Stroke tissue plasminogen activator studies following European Cooperative Acute Stroke Study III patient selection criteria. J Stroke Cerebrovasc Dis (2010) 0.84
Defining the ischemic penumbra using magnetic resonance oxygen metabolic index. Stroke (2015) 0.84
Thrombolysis for cerebral ischemia. Front Neurol (2010) 0.83
Biomarkers for stroke. J Stroke (2013) 0.83
International survey of acute stroke imaging used to make revascularization treatment decisions. Int J Stroke (2015) 0.83
Assessment of the accuracy of a Bayesian estimation algorithm for perfusion CT by using a digital phantom. Neuroradiology (2013) 0.82
Fast neuroprotection (fast-NPRX) for acute ischemic stroke victims: the time for treatment is now. Transl Stroke Res (2013) 0.82
Resolving the negative data publication dilemma in translational stroke research. Transl Stroke Res (2011) 0.82
Recanalization and Reperfusion Therapies of Acute Ischemic Stroke: What have We Learned, What are the Major Research Questions, and Where are We Headed? Front Neurol (2014) 0.82
Clinical relevance and practical implications of trials of perfusion and angiographic imaging in patients with acute ischaemic stroke: a multicentre cohort imaging study. J Neurol Neurosurg Psychiatry (2013) 0.82
Stroke imaging research road map. Neuroimaging Clin N Am (2011) 0.82
SMTP-7, a novel small-molecule thrombolytic for ischemic stroke: a study in rodents and primates. J Cereb Blood Flow Metab (2013) 0.81
Cerebral Blood Volume ASPECTS Is the Best Predictor of Clinical Outcome in Acute Ischemic Stroke: A Retrospective, Combined Semi-Quantitative and Quantitative Assessment. PLoS One (2016) 0.81
Perfusion-CT guided intravenous thrombolysis in patients with unknown-onset stroke: a randomized, double-blind, placebo-controlled, pilot feasibility trial. Neuroradiology (2011) 0.81
Reperfusion therapies of acute ischemic stroke: potentials and failures. Front Neurol (2014) 0.81
Desmoteplase: discovery, insights and opportunities for ischaemic stroke. Br J Pharmacol (2012) 0.81
Intravenous thrombolytics for ischemic stroke. Neurotherapeutics (2011) 0.81
Imaging and treatment of patients with acute stroke: an evidence-based review. AJNR Am J Neuroradiol (2013) 0.81
Visual perfusion-diffusion mismatch is equivalent to quantitative mismatch. Stroke (2011) 0.81
Neuroimaging as a Selection Tool and Endpoint in Clinical and Pre-clinical Trials. Transl Stroke Res (2016) 0.80
The Effects of Methylene Blue on Autophagy and Apoptosis in MRI-Defined Normal Tissue, Ischemic Penumbra and Ischemic Core. PLoS One (2015) 0.80
Reversing stroke in the 2010s: lessons from Desmoteplase In Acute ischemic Stroke-2 (DIAS-2). Stroke (2009) 0.80
Early changes of tissue perfusion after tissue plasminogen activator in hyperacute ischemic stroke. Stroke (2010) 0.80
Alberta Stroke Program Early CT Score (ASPECTS) in patients with wake-up stroke. J Stroke Cerebrovasc Dis (2010) 0.80
Defining the ischemic penumbra using hyperacute neuroimaging: deriving quantitative ischemic thresholds. Transl Stroke Res (2012) 0.80
Drug treatment of acute ischemic stroke. Am J Cardiovasc Drugs (2013) 0.80
Spatial distribution of perfusion abnormality in acute MCA occlusion is associated with likelihood of later recanalization. J Cereb Blood Flow Metab (2014) 0.80
Stroke mismatch volume with the use of ABC/2 is equivalent to planimetric stroke mismatch volume. AJNR Am J Neuroradiol (2013) 0.79
The future of stroke imaging: what we need and how to get to it. Stroke (2010) 0.79
Reperfusion therapies for acute ischemic stroke: an update. Curr Cardiol Rev (2014) 0.79
Desmoteplase and imaging science. Lancet Neurol (2008) 0.79
Beyond the time window of intravenous thrombolysis: standing by or by stenting? Interv Neurol (2012) 0.79
Combining MRI with NIHSS thresholds to predict outcome in acute ischemic stroke: value for patient selection. AJNR Am J Neuroradiol (2014) 0.79
Intravoxel incoherent motion perfusion imaging in acute stroke: initial clinical experience. Neuroradiology (2014) 0.78
Fibrinolytic therapy in acute stroke. Curr Cardiol Rev (2010) 0.78
White matter ischemic changes in hyperacute ischemic stroke: voxel-based analysis using diffusion tensor imaging and MR perfusion. Stroke (2014) 0.78
Neuroimaging of cerebral ischemia and infarction. Neurotherapeutics (2011) 0.78
The value of patient selection in demonstrating treatment effect in stroke recovery trials: lessons from the CHIMES study of MLC601 (NeuroAiD). J Evid Based Med (2015) 0.78
Therapy in pediatric stroke. Eur J Pediatr (2012) 0.77
Plasminogen activators and ischemic stroke: conditions for acute delivery. Semin Thromb Hemost (2013) 0.77
Rapid identification of a major diffusion/perfusion mismatch in distal internal carotid artery or middle cerebral artery ischemic stroke. BMC Neurol (2012) 0.77
Thrombolysis in acute ischaemic stroke: an update. Ther Adv Chronic Dis (2011) 0.77
Stroke in 2011: Major advances across the spectrum of stroke care. Nat Rev Neurol (2012) 0.76
Clinically relevant reperfusion in acute ischemic stroke: MTT performs better than Tmax and TTP. Transl Stroke Res (2014) 0.76
Advances in medical revascularisation treatments in acute ischemic stroke. Thrombosis (2014) 0.76
Thrombolytic effects of the snake venom disintegrin saxatilin determined by novel assessment methods: a FeCl3-induced thrombosis model in mice. PLoS One (2013) 0.76
Two-hour improvement of patients in the National Institute of Neurological Disorders and Stroke trials and prediction of final outcome. Stroke (2011) 0.76
Brain Vascular Imaging Techniques. Int J Mol Sci (2016) 0.75
Impact of Slow Blood Filling via Collaterals on Infarct Growth: Comparison of Mismatch and Collateral Status. J Stroke (2016) 0.75
Evaluation of Cerebral Perfusion in Patients Undergoing Intravenous Recombinant Tissue Plasminogen Activator Thrombolysis. Neurol Med Chir (Tokyo) (2015) 0.75
Arterial Obstruction on Computed Tomographic or Magnetic Resonance Angiography and Response to Intravenous Thrombolytics in Ischemic Stroke. Stroke (2016) 0.75
Comparison of magnetic resonance imaging mismatch criteria to select patients for endovascular stroke therapy. Stroke (2014) 0.75
CT angiography predicts use of tertiary interventional services in acute ischemic stroke patients. Int J Emerg Med (2011) 0.75
Optimizing stroke clinical trial design: estimating the proportion of eligible patients. Stroke (2010) 0.75
The quest for arterial recanalization in acute ischemic stroke-the past, present and the future. J Clin Med Res (2013) 0.75
Tissue plasminogen activator for acute ischemic stroke. The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. N Engl J Med (1995) 47.15
Thrombolysis with alteplase 3 to 4.5 hours after acute ischemic stroke. N Engl J Med (2008) 28.42
Intravenous thrombolysis with recombinant tissue plasminogen activator for acute hemispheric stroke. The European Cooperative Acute Stroke Study (ECASS) JAMA (1995) 13.37
Association of outcome with early stroke treatment: pooled analysis of ATLANTIS, ECASS, and NINDS rt-PA stroke trials. Lancet (2004) 12.92
Magnetic resonance imaging profiles predict clinical response to early reperfusion: the diffusion and perfusion imaging evaluation for understanding stroke evolution (DEFUSE) study. Ann Neurol (2006) 10.51
Effects of alteplase beyond 3 h after stroke in the Echoplanar Imaging Thrombolytic Evaluation Trial (EPITHET): a placebo-controlled randomised trial. Lancet Neurol (2008) 9.02
The Thrombolysis in Myocardial Infarction (TIMI) trial. Phase I findings. TIMI Study Group. N Engl J Med (1985) 7.29
The Desmoteplase in Acute Ischemic Stroke Trial (DIAS): a phase II MRI-based 9-hour window acute stroke thrombolysis trial with intravenous desmoteplase. Stroke (2004) 4.39
Perfusion-CT assessment of infarct core and penumbra: receiver operating characteristic curve analysis in 130 patients suspected of acute hemispheric stroke. Stroke (2006) 3.49
Dose Escalation of Desmoteplase for Acute Ischemic Stroke (DEDAS): evidence of safety and efficacy 3 to 9 hours after stroke onset. Stroke (2006) 3.03
Enlargement of human cerebral ischemic lesion volumes measured by diffusion-weighted magnetic resonance imaging. Ann Neurol (1997) 2.80
Comparison of admission perfusion computed tomography and qualitative diffusion- and perfusion-weighted magnetic resonance imaging in acute stroke patients. Stroke (2002) 2.56
Comparison of CT perfusion and angiography and MRI in selecting stroke patients for acute treatment. Neurology (2007) 1.42
In vitro stimulation of tissue-type plasminogen activator by Alzheimer amyloid beta-peptide analogues. Nat Med (1995) 1.20
Vampire bat salivary plasminogen activator (desmoteplase): a unique fibrinolytic enzyme that does not promote neurodegeneration. Stroke (2003) 1.16
Plasminogen activation is stimulated by prion protein and regulated in a copper-dependent manner. Biochemistry (2002) 1.13
Thrombolysis with alteplase 3 to 4.5 hours after acute ischemic stroke. N Engl J Med (2008) 28.42
Defining and setting national goals for cardiovascular health promotion and disease reduction: the American Heart Association's strategic Impact Goal through 2020 and beyond. Circulation (2010) 13.28
Association of outcome with early stroke treatment: pooled analysis of ATLANTIS, ECASS, and NINDS rt-PA stroke trials. Lancet (2004) 12.92
Time to treatment with intravenous alteplase and outcome in stroke: an updated pooled analysis of ECASS, ATLANTIS, NINDS, and EPITHET trials. Lancet (2010) 12.21
Thrombolysis with alteplase for acute ischaemic stroke in the Safe Implementation of Thrombolysis in Stroke-Monitoring Study (SITS-MOST): an observational study. Lancet (2007) 10.74
A trial of imaging selection and endovascular treatment for ischemic stroke. N Engl J Med (2013) 9.97
Magnetic resonance imaging and computed tomography in emergency assessment of patients with suspected acute stroke: a prospective comparison. Lancet (2007) 8.68
Trial design and reporting standards for intra-arterial cerebral thrombolysis for acute ischemic stroke. Stroke (2003) 7.75
Telmisartan to prevent recurrent stroke and cardiovascular events. N Engl J Med (2008) 7.25
Aspirin and extended-release dipyridamole versus clopidogrel for recurrent stroke. N Engl J Med (2008) 6.08
Cerebral microbleeds: a guide to detection and interpretation. Lancet Neurol (2009) 6.02
MRI profile and response to endovascular reperfusion after stroke (DEFUSE 2): a prospective cohort study. Lancet Neurol (2012) 5.91
Recombinant human erythropoietin in the treatment of acute ischemic stroke. Stroke (2009) 5.28
Time to treatment with intravenous tissue plasminogen activator and outcome from acute ischemic stroke. JAMA (2013) 5.05
Comparison of MRI and CT for detection of acute intracerebral hemorrhage. JAMA (2004) 4.82
The Desmoteplase in Acute Ischemic Stroke Trial (DIAS): a phase II MRI-based 9-hour window acute stroke thrombolysis trial with intravenous desmoteplase. Stroke (2004) 4.39
Vorapaxar in the secondary prevention of atherothrombotic events. N Engl J Med (2012) 4.10
Short-term outcome after stenting versus endarterectomy for symptomatic carotid stenosis: a preplanned meta-analysis of individual patient data. Lancet (2010) 4.07
Update to the AHA/ASA recommendations for the prevention of stroke in patients with stroke and transient ischemic attack. Stroke (2008) 4.06
Effect of ezetimibe coadministered with atorvastatin in 628 patients with primary hypercholesterolemia: a prospective, randomized, double-blind trial. Circulation (2003) 3.81
Recommendations for the establishment of stroke systems of care: recommendations from the American Stroke Association's Task Force on the Development of Stroke Systems. Stroke (2005) 3.74
Ezetimibe coadministered with simvastatin in patients with primary hypercholesterolemia. J Am Coll Cardiol (2002) 3.64
White matter tractography using diffusion tensor deflection. Hum Brain Mapp (2003) 3.50
Perfusion-CT assessment of infarct core and penumbra: receiver operating characteristic curve analysis in 130 patients suspected of acute hemispheric stroke. Stroke (2006) 3.49
Analysis of 1008 consecutive patients aged 15 to 49 with first-ever ischemic stroke: the Helsinki young stroke registry. Stroke (2009) 3.39
Timeliness of tissue-type plasminogen activator therapy in acute ischemic stroke: patient characteristics, hospital factors, and outcomes associated with door-to-needle times within 60 minutes. Circulation (2011) 3.30
DWI-FLAIR mismatch for the identification of patients with acute ischaemic stroke within 4·5 h of symptom onset (PRE-FLAIR): a multicentre observational study. Lancet Neurol (2011) 3.18
Reliability of clinical guidelines in the detection of patients at risk following mild head injury: results of a prospective study. J Neurosurg (2004) 3.10
Risks of intracranial hemorrhage among patients with acute ischemic stroke receiving warfarin and treated with intravenous tissue plasminogen activator. JAMA (2012) 3.07
Dose Escalation of Desmoteplase for Acute Ischemic Stroke (DEDAS): evidence of safety and efficacy 3 to 9 hours after stroke onset. Stroke (2006) 3.03
Prognosis and safety of anticoagulation in intracranial artery dissections in adults. Stroke (2007) 2.95
Reducing in-hospital delay to 20 minutes in stroke thrombolysis. Neurology (2012) 2.91
Factors influencing the decline in stroke mortality: a statement from the American Heart Association/American Stroke Association. Stroke (2013) 2.88
A pilot study of focused ultrasound thalamotomy for essential tremor. N Engl J Med (2013) 2.82
Diffusion tensor imaging as potential biomarker of white matter injury in diffuse axonal injury. AJNR Am J Neuroradiol (2004) 2.78
Thrombolysis of basilar artery occlusion: impact of baseline ischemia and time. Ann Neurol (2013) 2.77
A review of the evidence for the use of telemedicine within stroke systems of care: a scientific statement from the American Heart Association/American Stroke Association. Stroke (2009) 2.74
Utilization of intravenous tissue plasminogen activator for acute ischemic stroke. Arch Neurol (2004) 2.65
Predictors of adherence to performance measures in patients with acute myocardial infarction. Am J Med (2012) 2.64
Prehospital thrombolysis in acute stroke: results of the PHANTOM-S pilot study. Neurology (2012) 2.60
Comparative overview of brain perfusion imaging techniques. Stroke (2005) 2.59
Recommendations for imaging of acute ischemic stroke: a scientific statement from the American Heart Association. Stroke (2009) 2.55
Early blood-brain barrier disruption in human focal brain ischemia. Ann Neurol (2004) 2.54
Clinical and angiographic risk factors for stroke and death within 30 days after carotid endarterectomy and stent-protected angioplasty: a subanalysis of the SPACE study. Lancet Neurol (2008) 2.53
Recommendations on angiographic revascularization grading standards for acute ischemic stroke: a consensus statement. Stroke (2013) 2.50
Safety of thrombolysis in stroke mimics: results from a multicenter cohort study. Stroke (2013) 2.44
Systematic comparison of perfusion-CT and CT-angiography in acute stroke patients. Ann Neurol (2007) 2.44
MRI versus CT-based thrombolysis treatment within and beyond the 3 h time window after stroke onset: a cohort study. Lancet Neurol (2006) 2.42
NXY-059 for the treatment of acute stroke: pooled analysis of the SAINT I and II Trials. Stroke (2008) 2.39
Recommendations for the establishment of stroke systems of care: recommendations from the American Stroke Association's Task Force on the Development of Stroke Systems. Circulation (2005) 2.38
Comparison of 30-day mortality models for profiling hospital performance in acute ischemic stroke with vs without adjustment for stroke severity. JAMA (2012) 2.38
Granulocyte colony-stimulating factor in patients with acute ischemic stroke: results of the AX200 for Ischemic Stroke trial. Stroke (2013) 2.36
Bleeding risk analysis in stroke imaging before thromboLysis (BRASIL): pooled analysis of T2*-weighted magnetic resonance imaging data from 570 patients. Stroke (2007) 2.36
Comparison of CT and CT angiography source images with diffusion-weighted imaging in patients with acute stroke within 6 hours after onset. Stroke (2002) 2.33
Potential intracranial applications of magnetic resonance-guided focused ultrasound surgery. J Neurosurg (2012) 2.32
Diagnostic and prognostic value of early MR Imaging vessel signs in hyperacute stroke patients imaged <3 hours and treated with recombinant tissue plasminogen activator. AJNR Am J Neuroradiol (2005) 2.28
Recommendations for the implementation of telemedicine within stroke systems of care: a policy statement from the American Heart Association. Stroke (2009) 2.26
Age-related differences in characteristics, performance measures, treatment trends, and outcomes in patients with ischemic stroke. Circulation (2010) 2.15
Hospital-level variation in mortality and rehospitalization for medicare beneficiaries with acute ischemic stroke. Stroke (2010) 2.12
Selection of acute ischemic stroke patients for intra-arterial thrombolysis with pro-urokinase by using ASPECTS. Stroke (2003) 2.12
Smoking-thrombolysis paradox: recanalization and reperfusion rates after intravenous tissue plasminogen activator in smokers with ischemic stroke. Stroke (2013) 2.11
Correlation of diffusion tensor tractography and intraoperative macrostimulation during deep brain stimulation for Parkinson disease. J Neurosurg (2014) 2.11
Neuraxial anesthesia in parturients with intracranial pathology: a comprehensive review and reassessment of risk. Anesthesiology (2013) 2.09
Perfusion-weighted imaging/diffusion-weighted imaging mismatch on MRI can now be used to select patients for recombinant tissue plasminogen activator beyond 3 hours: pro. Stroke (2005) 2.06
Transcranial magnetic resonance-guided focused ultrasound surgery for trigeminal neuralgia: a cadaveric and laboratory feasibility study. J Neurosurg (2012) 2.04
Case records of the Massachusetts General Hospital. Weekly clinicopathological exercises. Case 5-2004 - a 57-year-old man with slurred speech and left hemiparesis. N Engl J Med (2004) 2.04
Poor outcomes in patients who do not receive intravenous tissue plasminogen activator because of mild or improving ischemic stroke. Stroke (2005) 2.03
Characteristics, performance measures, and in-hospital outcomes of the first one million stroke and transient ischemic attack admissions in get with the guidelines-stroke. Circ Cardiovasc Qual Outcomes (2010) 2.02
Early reperfusion and clinical outcomes in patients with M2 occlusion: pooled analysis of the PROACT II, IMS, and IMS II studies. J Neurosurg (2014) 2.01
A 62-year-old man with fluctuating neurological deficits and skin lesions. JAMA Neurol (2013) 1.99
Fluid-attenuated inversion recovery evolution within 12 hours from stroke onset: a reliable tissue clock? Stroke (2009) 1.99
Peripartum subarachnoid hemorrhage: nationwide data and institutional experience. Anesthesiology (2012) 1.98
Longitudinal changes in patients with traumatic brain injury assessed with diffusion-tensor and volumetric imaging. Neuroimage (2008) 1.97